ストックスクリーナーアプリを入手
4.37
6.07%
0.25
アフターアワーズ：
4.16
-0.21
-4.81%
Aquestive Therapeutics Inc (AQST) 最新ニュース
Aquestive Therapeutics Inc. (AQST) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Aquestive Therapeutics Q4 Loss Widens, Revenue Rises; Shares Fall After Hours - marketscreener.com
Aquestive Therapeutics Amends RTW Deal, Strengthens Financing Outlook - TipRanks
Aquestive Therapeutics (NASDAQ:AQST) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPS - MarketBeat
Aquestive Therapeutics: Q4 Earnings Snapshot - KING5.com
Regulatory setbacks hit Aquestive (NASDAQ: AQST) lead drugs Anaphylm, Libervant - Stock Titan
Anaphylm CRL and 2025 loss shape Aquestive (NASDAQ: AQST) outlook - Stock Titan
Aquestive Therapeutics Q4 Earnings Assessment - Benzinga
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Yahoo Finance Singapore
A Preview Of Aquestive Therapeutics's Earnings - Benzinga
AQST SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP - GlobeNewswire
AQST Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aquestive Therapeutics, Inc.Common Stock (NQ: AQST - The Chronicle-Journal
Aquestive Therapeutics Inc (AQST) - MSN
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - PR Newswire
Aquestive Therapeutics Inc. (AQST) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aquestive Therapeutics Touts Anaphylm, Targets Q3 FDA Resubmission After CRL at Oppenheimer Conference - MarketBeat
Lake Street adjusts Aquestive Therapeutics, Inc. (AQST) valuation model on expected approval delay - MSN
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - GlobeNewswire
Aquestive Highlights Strategy, Pipeline and Risk Disclosures - TipRanks
Aquestive Therapeutics files investor presentation detailing Anaphylm plan, CRL resubmission timeline and cash position - TradingView
Aquestive Therapeutics Forms Death Cross, Signaling Potential Bearish Trend - Markets Mojo
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences - Investing News Network
Aquestive Therapeutics (AQST) to Release Earnings on Wednesday - MarketBeat
AQST INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - marketscreener.com
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET - Investing News Network
Aquestive Therapeutics to Report Fourth Quarter 2025 - GlobeNewswire
Lake Street Adjusts Aquestive Therapeutics, Inc. (AQST) Valuation Model on Expected Approval Delay - Insider Monkey
Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
Pharma company Aquestive joins Oppenheimer’s virtual healthcare investor event - Stock Titan
625,000 Shares in Aquestive Therapeutics, Inc. $AQST Acquired by Aberdeen Group plc - MarketBeat
Is Aquestive Therapeutics Inc. forming a bullish divergenceJuly 2025 Setups & Free High Return Stock Watch Alerts - mfd.ru
Aquestive Therapeutics to Present New Clinical Data on Anaphylm (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting - Bitget
Aquestive Therapeutics Announces Clinical Results for Anaphylm™ Sublingual Film at AAAAI Annual Meeting - Quiver Quantitative
Allergy film Anaphylm delivers epinephrine without blood pressure dip in study - Stock Titan
Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting - Yahoo Finance
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer - The Globe and Mail
Analyst Upgrade: Will Aquestive Therapeutics Inc benefit from government policyQuarterly Growth Report & Weekly High Conviction Ideas - baoquankhu1.vn
Aquestive appoints allergy expert Dr. Greenhawt as chief medical officer - Investing.com
2026-02-18 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse
Aquestive Therapeutics Appoints Dr. Matthew Greenhawt as Chief Medical Officer - citybiz
Aquestive appoints allergy expert Dr. Greenhawt as chief medical officer By Investing.com - Investing.com Canada
Aquestive Therapeutics Appoints Dr. Matthew Greenhawt as Chief Medical Officer to Advance Anaphylm™ NDA Resubmission - Quiver Quantitative
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - Nasdaq
Aquestive Therapeutics: Biology Validated, Packaging PendingA Forensic Analysis Of The Anaphylm CRL - Seeking Alpha
Aquestive Therapeutics Faces FDA Setback for Anaphylm Drug - National Today
AQST SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - marketscreener.com
AQST SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP - GlobeNewswire
Can Aquestive Therapeutics Inc. stock resist sector downturnsDollar Strength & Weekly Market Pulse Updates - mfd.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc.AQST - PR Newswire
2026-02-12 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse
0.21%
1.77%
大文字化:
|
ボリューム (24 時間):